Drug Discovery and the Market Today Part 5: Considering Genotoxic and Carcinogenic Impurities

Posted: 06/10/2010
To continue viewing this content please fill out the form below and become an Pharma IQ member.
Or if you're already a Pharma IQ member, sign in below to download.
Join

By entering in your information and submitting the form, you give the sponsor permission to contact you regarding their product and you agree to our User Agreement, Privacy Policy, and Cookie Policy.


Dr. David Elder, the Externalization Director for GlaxoSmithKline, talks exclusively to Pharma IQ on his perspective across the industry, including CROs, regulations, and strategising for efficiency.

Contributor: